Kestine (ebastine) a fost folosit de autori in tratamentul unui lot de 37 de persoane (10 spitalizate si 27 tratate ambulator) cu suferinte cutanate cu mecanism alergic. Ebastina si metabolismul ei activ carebastina sunt preparate cu actiune inhibitorie selectiva asupra receptorilor H1 periferici fiind simultan lipsite de activitate asupra sistemului nervos central si neavand actiune anticolinergica. Autorii au administrat cate 1 cp. de 10 mg (doza unica) la un lot de 37 de pacienti (17 femei si 20 barbati) cu varste intre 17 si 82 de ani cu afectiuni cutanate cu mecanism alergic. Bolnavii studiati (11 cu urticarie, 7 cu eczema, 7 cu prurigo cronic, 5 cu alergodermii postmedicamentoase, 3 cu vasculita alergica purpurica, 2, cu eritem nodos si 2 cu neurodermita) au beneficiat asociat de tratamentele locale clasice corespunzatoare si dietoterapie hipoalergenica.

Pacientii cercetati erau toti la al 2-lea sau al 3-lea puseu si folosisera in episoadele precedente alte histaminice. Rezultatele favorabile obtinute de noi au fost evidente, constand din diminuarea sau chiar disparitia pruritului dupa diminuarea sau chiar disparitia pruritului dupa a 3-a zi de tratament, reducerea leziunilor eritemato-edematoase in medie dupa 3-5 zile de tratament si remisiunea simptomelor cutanate la pacientii cu eczeme, vasculita purpurica, eritem nodos, prurigo si neurodermita dupa 10 zile de tratament.

In concluzie consideram ca Kestine este un antihistaminic eficient si competitiv, cu indicatie majora in tratamentul dermatozelor alergice.

Kestine (Ebastine) was used by the authors in cureing a group of 37 patients (10 hospitalized and 27 ambulatory treated) with all allergic cutaneous diseases. Ebastine and carebastine, its active metabolite, are selective inhibitory preparations acting on the peripheric H1 receptors, but simultaneously being inactive on the central nervous system and no anticholinergic action.

The authors gave one 10 mg capsule (unique doze) for each of the 37 patients (17 females and 20 males) aged between
17 and 82 years old with allergic cutaneous diseases.

Patients studies by us (11 of which having rash, 7 with eczema, 7 with chronic prurigo, 5 with postmedicamentous allergodermia, 3 with purpuric allergic vasculitis, 2 with nodular eritema and 2 with neurodermitis) benefitted associately of corresponding clasic local treatment and hipoallergic dietotherapy.

Patients were all at the second or third crises and they had used another antihystaminal during their previous episodes.

Our favourable results were obvious and they led to diminishing or even disappearing the pruritus after the third day treatment; it also reduced the eritemic-edematous lesions after an average of 3-5 day treatment an cutaneous symptoms remission in patients having eczemas, purpuric vasculitis, nodular eritema, prurigo and neurodermitis occured after a 10 day treatment.

As a conclusion we can state that Kestine is an efficient and competitive antihistaminic with a major recommendation in allergic dermatosis treatment.